As the GLP-1R agonists, ByettaTM and VictozaTM, have been used for the treatment of patients with type II diabetes mellitus, the concentration of GLP-1 used in this study can have pharmacological significance. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.